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Abstract
As miRNAs are associated with normal cellular processes, deregulation of miRNAs is thought to play a causative role in many
complex diseases. Nevertheless, the precise contribution of miRNAs in fibrotic lung diseases, especially the idiopathic form
(IPF), remains poorly understood. Given the poor response rate of IPF patients to current therapy, new insights into the
pathogenic mechanisms controlling lung fibroblasts activation, the key cell type driving the fibrogenic process, are essential
to develop new therapeutic strategies for this devastating disease. To identify miRNAs with potential roles in lung
fibrogenesis, we performed a genome-wide assessment of miRNA expression in lungs from two different mouse strains
known for their distinct susceptibility to develop lung fibrosis after bleomycin exposure. This led to the identification of miR-
199a-5p as the best miRNA candidate associated with bleomycin response. Importantly, miR-199a-5p pulmonary expression
was also significantly increased in IPF patients (94 IPF versus 83 controls). In particular, levels of miR-199a-5p were selectively
increased in myofibroblasts from injured mouse lungs and fibroblastic foci, a histologic feature associated with IPF.
Therefore, miR-199a-5p profibrotic effects were further investigated in cultured lung fibroblasts: miR-199a-5p expression
was induced upon TGFb exposure, and ectopic expression of miR-199a-5p was sufficient to promote the pathogenic
activation of pulmonary fibroblasts including proliferation, migration, invasion, and differentiation into myofibroblasts. In
addition, we demonstrated that miR-199a-5p is a key effector of TGFb signaling in lung fibroblasts by regulating CAV1, a
critical mediator of pulmonary fibrosis. Remarkably, aberrant expression of miR-199a-5p was also found in unilateral ureteral
obstruction mouse model of kidney fibrosis, as well as in both bile duct ligation and CCl4-induced mouse models of liver
fibrosis, suggesting that dysregulation of miR-199a-5p represents a general mechanism contributing to the fibrotic process.
MiR-199a-5p thus behaves as a major regulator of tissue fibrosis with therapeutic potency to treat fibroproliferative diseases.
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Introduction
Tissue fibrosis, defined as the excessive and persistent formation
of non functional scar tissue in response to repeated injury and
insult, is a leading cause of morbidity and mortality associated with
organ failure in various chronic diseases such as those affecting the
lung interstitium [1]. Among the interstitial lung diseases of
unknown etiology, Idiopathic Pulmonary Fibrosis (IPF) is the most
common and lethal with a median survival of 3 to 5 years after
diagnosis [2]. The pathogenesis of IPF is complex and largely
unknown [2], but observations based on both animal models of
pulmonary fibrosis and lung sections from patients with IPF
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suggest a dynamic pathobiological process involving excessive
wound healing with chronic inflammation, apoptosis of epithelial
and endothelial cells, mesenchymal cell proliferation and activa-
tion with the formation of fibroblasts/myofibroblasts foci, and
finally excessive deposition of extracellular matrix resulting in the
destruction of the lung architecture and the loss of lung functions
[2]. In particular, myofibroblasts play a substantial role in IPF by
secreting important amount of ECM components and by
promoting lung tissue stiffening [3]. Given the poor response rate
of IPF patients to current therapy, a detailed understanding of the
underlying pathogenic mechanisms is of major interest to develop
new effective therapeutic strategies targeting the cellular and
molecular events involved in the fibrotic response.
MicroRNAs (miRNAs) are a class of noncoding small RNA,
which most often bind to the 39 UTR of target genes mRNAs and
thereby repress their translation and/or induce their degradation.
Since the first miRNA identification in Caenorhabditis elegans in a
context of larval development [4,5], thousands miRNAs have now
been characterized including about 2000 in human (miRbase v19)
[6]. MiRNAs are now recognized as major regulators of gene
expression with crucial functions in numerous biological processes
including development, proliferation, differentiation, apoptosis
and stress response. Importantly, recent studies have identified
specific miRNA expression patterns related to the initiation and
progression of various diseases including cancer as well as
inflammatory, infectious and autoimmune diseases [7–9]. Addi-
tionally, gain and loss of function miRNA studies have further
established their functional impact in various in vivo models [10–
15]. Nevertheless, the precise contribution of miRNAs in fibrotic
diseases, especially lung fibrosis, is still poorly understood [16,17].
Our rationale was therefore to test whether miRNAs may provide
new perspectives on disease mechanisms, diagnosis as well as new
therapeutic opportunities in the specific context of fibrosis.
In an effort to identify miRNAs with potential roles in the
development of lung fibrosis (strategy detailed in Figure S1), we
aimed to identify miRNAs of interest in two mouse strains showing
different susceptibility to develop lung fibrosis after bleomycin
exposure. This led to the identification of a panel of miRNAs
specifically dysregulated in the lungs of fibrosis prone mouse strain
in response to bleomycin. Among these miRNAs, miR-199a-5p
was found to be selectively up-regulated in myofibroblasts of the
injured lung in bleomycin-treated mice and fibroblastic foci of IPF
patients. In lung fibroblasts, miR-199a-5p acts as an effector of
TGFb signaling, regulates CAV1 expression, a critical mediator of
the lung fibrosis process [18–21] and participates to multiple
fibrogenic associated-processes including cell proliferation, migra-
tion, invasion and differentiation into myofibroblasts. Finally,
dysregulation of miR-199a-5p was also found in two other mouse
models of tissue fibrosis, namely kidney fibrosis and liver fibrosis,
suggesting therefore that miR-199a-5p is likely to be a common
mediator of fibrosis.
Results
Fibrosis-sensitive and -resistant mice exhibit a distinct
miRNA expression profile in response to bleomycin
Previous studies based on mice have demonstrated a genetic
susceptibility to bleomycin-induced pulmonary fibrosis [22,23].
Indeed, C57BL/6 mice are considered to be fibrosis prone,
whereas BALB/C mice are less prone to fibrosis. To identify
miRNAs that may contribute to the lung fibrosis process, miRNA
expression profile in response to bleomycin was assessed 7 days
and 14 days following bleomycin administration (i.e. when active
fibrogenesis occurs) on both strains using a microarray based
platform (Data set 1, GEO accession number GSE34812)
described elsewhere [24–26]. We identified 22 differentially
expressed miRNAs between lungs from bleomycin- and control-
treated animals in at least one strain, the majority being
upregulated in bleomycin-instillated lungs (Figure 1A). We focused
our analysis on miRNAs that exhibited an enhanced expression in
response to bleomycin during disease progression in the C57BL/6
sensitive mice only. Among several miRNAs candidates with such
a profile, miR-199a-5p displayed the highest statistical score
(Figure 1B). This was further established using an independent set
of mice at day 14 following bleomycin treatment (Figure S2A).
These findings strongly suggested that miR-199a-5p may play an
important role during the lung fibrosis process. To investigate the
regulatory mechanisms underlying miR-199a-5p production, we
assessed the expression status of the 2 mouse genes, miR-199a-1
(on chromosome 9) and miR-199a-2 (on chromosome 1) in
response to bleomycin using a Taqman assay designed to
discriminate between pri-miR-199a-1 and pri-miR-199a-2. Our
results showed that, 14 days after bleomycin instillation, both pri-
miR-199a transcripts were up-regulated in the lungs of C57BL/6
mice (Figure S2B) and thus, contributed to miR-199a-5p
production. In addition, in situ hybridization experiments per-
formed in the injured lungs from C57BL/6 mice 14 days after
bleomycin instillation revealed a selective expression of miR-199a-
5p in myofibroblasts (Figure 1C).
Of note, consistent with previous findings [14], we also found a
significant upregulation of miR-21 (now referenced in miRbase as
mmu-miR-21a-5p) in response to bleomycin (Figure 1A and
Figure S3). Nevertheless, miR-21 induction did not differ between
bleomycin-sensitive and bleomycin-resistant strains of mice.
Identification of miR-199a-5p target genes in lung
fibroblasts
We next sought to determine the mechanism by which miR-
199a-5p dysregulation may lead to tissue fibrosis. To address this
question, we first attempted to identify gene targets and cellular
pathways regulated by miR-199a-5p using the methodology
described earlier [25,26]. The influence of miR-199a-5p on
Author Summary
Fibrosis is the final common pathway in virtually all forms
of chronic organ failure, including lung, liver, and kidney,
and is a leading cause of morbidity and mortality
worldwide. Fibrosis results from the excessive activity of
fibroblasts, in particular a differentiated form known as
myofibroblast that is responsible for the excessive and
persistent accumulation of scar tissue and ultimately organ
failure. Idiopathic Lung Fibrosis (IPF) is a chronic and often
rapidly fatal pulmonary disorder of unknown origin
characterized by fibrosis of the supporting framework
(interstitium) of the lungs. Given the poor prognosis of IPF
patients, new insights into the biology of (myo)fibroblasts
is of major interest to develop new therapeutics aimed at
reducing (myo)fibroblast activity to slow or even reverse
disease progression, thereby preserving organ function
and prolonging life. MicroRNAs (miRNAs), a class of non-
coding RNA recently identified, are associated with normal
cellular processes; and deregulation of miRNAs plays a
causative role in a vast array of complex diseases. In this
study, we identified a particular miRNA: miR-199a-5p that
governs lung fibroblast activation and ultimately lung
fibrosis. Overall we showed that miR-199a-5p is a major
regulator of fibrosis with strong therapeutic potency to
treat fibroproliferative diseases such as IPF.
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Figure 1. miR-199a-5p expression during bleomycin induced lung fibrosis. (A) Heat map representing the statistically significant (adjusted
p-value,0.05) differentially expressed microRNAs in lungs from BALB/C and C57BL/6 mice in response to bleomycin at the indicated time points. Up-
regulated microRNAs are shown in progressively brighter shades of red, depending on the fold difference, and down-regulated microRNAs are shown
in progressively brighter shades of green. miR-199a-5p is marked in red. n = 3 mice in each group. (B) miR-199a-5p expression in lungs from BALB/C
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human pulmonary hFL1 fibroblast transcriptome was compared
with that of miR-21, which has been previously associated with the
development of fibrotic diseases including lung fibrosis [14,15,27]
(Data set 2, GEO accession number GSE34815). Forty-eight hours
after ectopic overexpression of each miRNA, a significant
alteration (defined by an absolute log2ratio above 0.7 and an
adjusted p-value below 0.05) of 1261 and 753 transcripts was
detected in the miR-199a-5p and miR-21 conditions, respectively.
While these 2 miRNAs induced very distinct gene expression
patterns (Figure 2A), a functional annotation of these signatures,
using Ingenuity Pathway software, indicated an overlap for
‘‘canonical pathways’’ including ‘‘Cell Cycle regulation’’ and
‘‘TGFb Signaling’’ (Table S1). Consistent with previous findings
[28], highly significant pathways associated with miR-21 were
related to ‘‘Cyclins and Cell Cycle Regulation’’ as well as ‘‘Cell
Cycle Control of Chromosomal Replication’’, ‘‘Mismatch Repair
in Eukaryotes’’ and ‘‘ATM signalling’’. While the highest scoring
pathway for miR-199a-5p corresponded to the metabolic path-
ways ‘‘Biosynthesis of Steroids’’, we also noticed enrichment for
pathways related to ‘‘Integrin Signaling’’ and ‘‘Caveolar-mediated
Endocytosis Signaling’’. We next looked for an enrichment of
putative direct targets in the population of down-regulated
transcripts, as described in [29]. A specific overrepresentation of
predicted targets for miR-199a-5p and miR-21 in the population
of down-regulated transcripts was noticed after heterologous
expression of either miR-199a-5p or miR-21, respectively. This
enrichment was independent of the prediction tool used to define
the targets (Figure 2B and not shown). We then focussed our
analysis on a subset of 21 transcripts containing miR-199a-5p
complementary hexamers in their 39UTR, showing the largest
inhibition of expression, and identified by TargetScan, PicTar and
miRanda (Figure 2C and Table 1). The gene list of interest was
further narrowed by focussing on targets also associated with the
most significant canonical pathways described above. Interesting-
ly, the expression levels of 4 out of 21 mouse orthologs were also
significantly down-regulated in C57BL/6 mice 14 days after
instillation of bleomycin (Data set 3, GEO accession number
GSE34814, Table S2). These targets, highlighted in Table 1, are
ARHGAP12, CAV1, MAP3K11 and MPP5. Based on previous
studies that demonstrated a significant link between the downreg-
ulation of caveolin-1 (CAV1) in lung fibroblasts and the deleterious
effects mediated by TGFb [19,30], CAV1 represented a particu-
larly relevant putative miR-199a-5p target gene.
CAV1 is a bona fide miR-199a-5p target
Alignment of miR-199a-5p with human CAV1 39UTR
sequence revealed one potential conserved seed site (Figure 3A).
We then fused part of the human CAV1 39UTR to a luciferase
reporter using the psiCHEK-2 vector and transfected it into
HEK293 cells in the presence of either a pre-miR-199a-5p mimic
or a pre-miR-control (Figure 3B). As a control, we also used a
CAV1 39UTR construct mutated on the predicted miR-199a-5p
site. Human pre-miR-199a-5p induced a significant decrease in
the normalized luciferase activity relative to control in the
presence of the wild type construction only, confirming that it
represents a functional site. Moreover, this inhibition was also
repeated using the whole 39-UTR of human CAV1 (Figure S4),
demonstrating that CAV1 is indeed a direct target of miR-199a-5p.
Finally, transfection of pre-miR-199a-5p into MRC-5 and hFL1
lung fibroblasts led to a significant and specific decrease of CAV1
at both mRNA and protein levels while miR-21 had no significant
effect (Figure 3C–3E and Figure S5).
miR-199a-5p mediates TGFb-induced downregulation of
CAV1 in pulmonary fibroblasts
As TGFb is known to downregulate CAV1 in pulmonary
fibroblasts [19], we then investigated whether decreased expres-
sion of CAV1 upon TGFb stimulation was associated with an
increase in miR-199a-5p expression. We exposed the MRC-5 cell
line to TGFb, and analyzed the expression levels of CAV1 and
miR-199a-5p. As detected by Taqman RT-PCR, TGFb treatment
of human fibroblasts for 24 h or 48 h caused a marked decrease of
CAV1 mRNA, whereas miR-199a-5p expression was significantly
upregulated (Figure 4A and 4B). Decrease of CAV1 protein levels
after TGFb treatment was time dependent (Figure 4C). To further
investigate whether miR-199a-5p is involved in TGFb-induced
downregulation of CAV1, we performed additional experiments
using a LNA-based inhibitor of miR-199a-5p as well as a CAV1
target site blocker to specifically interfere with miR-199a-5p
binding on CAV1 39UTR. As depicted in Figure 4D and S6, both
LNA-mediated silencing of miR-199a-5p and blocking miR-199a-
5p binding on CAV1 39UTR inhibit TGFb-induced downregu-
lation of CAV1. Altogether, these experiments demonstrate that,
in lung fibroblasts, induction of miR-199a-5p in response to TGFb
mediates CAV1 downregulation through binding on a unique site
located in CAV1 39UTR.
Altered expression of CAV1 in the lungs of bleomycin
induced pulmonary fibrosis mice
We then assessed the expression of CAV1 in the fibrotic lungs of
mice. Consistent with previous studies [19,31], our data showed a
significant decrease in both CAV1 mRNA and protein expression
levels in C57Bl/6 mice 14 days after bleomycin administration
(Figure 5A–5C). Additionally, immunohistochemistry staining of
CAV1 on lung tissue sections from C57Bl/6 mice 14 days after
bleomycin treatment revealed a marked reduction of CAV1 in
fibrotic area of the lungs (Figure 5D). Taken together, these
experiments show that the observed up-regulation of miR-199a-5p
expression in the fibrotic lungs of mice is correlated with a
downregulation of CAV1. Of note, BALB/c mice, for which
pulmonary expression of miR-199a-5p was not upregulated in
response to bleomycin, did not display a significant decrease in
CAV1 mRNA expression level 14 days after bleomycin treatment
(Figure S7).
Concomitant altered expression of both CAV1 and miR-
199a-5p in lungs of IPF patients
Expression of miR-199a-5p expression was increased in lungs of
IPF patients (GEO accession number GSE13316 from [13];
dataset consisting of ten IPF samples and ten control samples; two
different probes for miR-199a-5p with a p-value of p = 0.005 and
p= 0.006, wilcoxon rank sum test, Table S3). This result was
confirmed with an independent dataset composed of 94 IPF and
83 control lungs (p,0.001) (Figure 6A) and in an additional cohort
using qPCR (Figure S8). As observed in mice, IPF samples also
and C57BL/6 mice in response to bleomycin at the indicated time points. n = 3 mice in each group. Data from microarrays experiments are expressed
as mean of normalized fluorescence intensity 6 SEM. **p,0.01 (C) Paraffin sections were prepared from lungs of C57BL/6 mice 14 days following
bleomycin intra-tracheal instillation. In situ hybridization and immunohistochemistry assays were performed to determine the colocalization of miR-
199a-5p and a-SMA. Results represent one out of three independently performed experiments.
doi:10.1371/journal.pgen.1003291.g001
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Figure 2. Identification of miR-199a-5p candidate targets using a transcriptomic approach. Normal human pulmonary fibroblasts hFL1
were transfected with pre-miR-Neg, pre-miR-199a-5p or pre-miR-21 (n = 2). RNA samples were harvested at 48 h post-transfection and expression
profiles were determined with pan genomic arrays. (A) Heatmap comparing the normalized log2 of the ratios between the signal in the different
conditions and the pre-miR-Neg signal. (B) Overrepresentation of miRNA predicted targets in the set of down-regulated transcripts following miR-
199a-5p and miR-21 transfection using the webtool miRonTop. Graphs show the significance of the enrichment, represented as 2log10 (adjusted p-
value), according to the fold enrichment using 2 different prediction tools for all known miRNAs: miR-199a-5p and miR-21 are represented as an open
diamond and triangle, respectively. Threshold values used to define the set of up- and down-regulated genes: AveExp= 7.0; log FC=0.7; adjusted p-
value = 0.05. (C) Venn diagram comparing the number of miR-199a-5p targets among the set of highly-downregulated genes following pre-miR-199a-
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exhibited a significant decrease in CAV1 expression (p,0.001)
(Figure 6B). The linear fold ratio for CAV1 between IPF and
control was 0.54 (FDR,0.05) and the linear fold ratio for miR-
199a-5p for the same subjects was 1.35 (p,0.05). Finally,
examination of IPF lung sections revealed a specific expression
of miR-199a-5p in fibroblastic foci of the injured lung as well as a
decreased CAV1 expression (Figure 6C and 6D).
MiR-199a-5p mediates fibrogenic activation of lung
fibroblasts through both CAV1-dependent and
-independent pathways
Given that loss of CAV1 expression represents a critical factor
involved in the fibrogenic activation of pulmonary fibroblasts [19],
we assessed whether overexpression of miR-199a-5p in lung
fibroblasts was sufficient to recapitulate known profibrotic effects
associated with a decrease in CAV1 expression (i.e. ECM
synthesis, fibroblasts proliferation, migration, invasion and differ-
entiation into myofibroblasts) [30,32,33]. Transfection of miR-
199a-5p precursors resulted in a significant induction of migration
(Figure 7A and 7B) and invasion (Figure 7C). In addition, cell cycle
analysis (percent cells in S phase) showed that proliferation rate of
pulmonary fibroblasts overexpressing miR-199a-5p was signifi-
cantly enhanced (Figure 7D). Finally, heterologous expression of
miR-199a-5p also led to a strong increase in a smooth mucle actin
(aSMA) expression (Figure 7E and Figure S9), a hallmark of
myofibroblast differentiation as well as to a significant potentiation
of COL1A1 induction in response to TGFb (Figure 7F).
Comparison of the gene expression profiles obtained in lung
fibroblasts transfected with miR-199a-5p precursors or with a
siRNA specifically directed against CAV1 revealed an overlap
between the 2 signatures, mainly among the down-regulated
transcripts (Figure S10A, group 2): 34% of miR-199a-5p
downregulated transcripts were also repressed by a siCAV1
(Figure S10B). To gain insights into the pathways modulated by
miR-199a-5p, Ingenuity Pathways canonical pathways associated
to miR-199a-5p were analyzed and compared to those of miR-21
and siCAV1 conditions. This analysis revealed some proximity
between miR-199a-5p and siCAV1 based on the existence of
shared regulated pathways (Figure 8A). Pathways that were
specific to miR-199a-5p were related to inflammation, such as
‘‘IL-1 Signaling’’, ‘‘Acute Phase Response Signaling’’ and ‘‘P38
MAPK Signaling’’, i.e. all typical of fibrotic processes. Important-
ly, several profibrotic genes were specifically regulated by miR-
199a-5p and their altered expression was confirmed in vivo (Figure
S11 and Table S4). MiR-199a-5p thus regulates multiple signaling
pathways involved in lung fibrogenesis. In particular, compared to
siCAV1 transfected cells, overexpression of miR-199a-5p signifi-
cantly increased CCL2, TGFBRI and MMP3 expression and
Table 1. List of the main miR-199a-5p predicted targets significantly downregulated following miR-199-5p overexpression in
human fibroblasts using the bioinformatics tool miRonTop (http://www.microarray.fr:8080/miRonTop/index).
Symbol Accession Number Description Av.Exp1 logFC2
ARHGAP123 NM_018287 Rho GTPase activating protein 12 11.12 21.96
C17orf63 NM_018182 - 11.90 21.58
CAV13 NM_001753 Caveolin 1, caveolae protein, 22 kDa (CAV1) 15.28 21.78
DDR1 NM_013993 Discoidin domain receptor tyrosine kinase 1 9.57 22.31
EPB41L1 NM_012156 Erythrocyte membrane protein band 4.1-like 1 12.88 21.94
EXTL3 NM_001440 Exostoses (multiple)-like 3 13.66 21.20
FZD6 NM_003506 Frizzled homolog 6 11.62 22.07
IPO8 NM_006390 Importin 8 12.00 22.09
KLHL3 NM_017415 Kelch-like 3 8.44 21.32
KPNA4 NM_002268 Karyopherin alpha 4 13.44 21.11
MAP3K113 NM_002419 Mitogen2activated protein kinase kinase kinase 11 13.11 22.77
MPP53 NM_022474 Membrane protein, palmitoylated 5 11.76 21.99
NLK NM_016231 Nemo-like kinase 11.36 21.63
PODXL NM_001018111 Podocalyxin-like (PODXL) 11.21 22.59
PPP1R2 NM_006241 Protein phosphatase 1, regulatory (inhibitor) subunit 2 11.29 22.50
PXN NM_002859 Paxillin 14.99 21.41
RNF11 NM_014372 Ring finger protein 11 14.30 21.09
ST6GAL1 NM_173216 ST6 beta-galactosamide alpha-2,6-sialyltranferase 1 10.67 21.70
TAF9B NM_015975 TAF9B RNA polymerase II, TATA box binding protein (TBP)-associated factor, 31 kDa 9.77 22.25
VPS26A NM_004896 Vacuolar protein sorting 26 homolog A 12.37 21.60
ZNF706 NM_001042510 Zinc finger protein 706 8.15 21.10
1logarithm (base 2) of the average intensity (AveExpr).
2logarithm (base 2) of the ratio of miR-199a-5p/miR-Neg (logFC).
3Expression significantly down-regulated in bleomycin-treated C57BL/6 mice.
doi:10.1371/journal.pgen.1003291.t001
5p transfection according to 3 distinct target prediction tools. Cut-offs for selection are equal to 7.0 for the log2 (signal), to 21.5 for the log2 (ratio),
and to 0.01 for the adjusted p-value.
doi:10.1371/journal.pgen.1003291.g002
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Figure 3. CAV1 is a direct target of miR-199a-5p. (A) Position of miR-199a-5p target site in CAV1 39 UTR and sequence alignment of miR-199a-
5p and the CAV1 39 UTR from various species are shown. The ‘‘seed’’ region with a conserved WC match to the eighth nucleotide of the miRNA is
highlighted. Bases that have been mutated in the psiCHECK-2 construct are underlined. (B) Co-transfection of pre-miR-199a-5p or pre-miR-Neg and
human CAV1 39UTR-derived psiCHECK-2 construct (wild type or mutated in the putative miR-199a-5p seed region) in HEK293 cells. Cells were
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significantly decreased CAV2 and PLAU expression (Figure S12).
Of note, these two downregulated genes were predicted to be
direct targets of miR-199a-5p by Pictar.
MiR-199a-5p is an effector of TGFb signaling in lung
fibroblasts by regulating CAV1
We next investigated whether miR-199a-5p is associated with
TGFb signaling. For this, we experimentally defined a TGFb
signaling signature in lung fibroblasts (Dataset 2, GSE34815) and
compared it to miR-199a-5p signature using gene set enrichment
analysis (GSEA) [34]. This analysis revealed a significant overlap
between these two signatures, as assessed by normalized enrich-
ment scores above 1 (1.4 and 2.17 for up- and down-regulated
genes respectively, with nominal p-value and FDR q-value being
,0.05), suggesting therefore, that miR-199a-5p is involved in the
TGFb response of lung fibroblasts (Figure 8B). To further
demonstrate the importance of miR-199a-5p in TGFb response,
silencing of miR-199a-5p was performed in lung fibroblasts using
LNA-based inhibitors. In particular, we showed that LNA-
mediated silencing of miR-199a-5p strongly inhibited TGFb-
induced differentiation of lung fibroblasts into myofibroblasts
(Figure 8C and Figure S6), SMAD signaling (Figure 8D) and
stimulation of wound repair (Figure 8E and 8F). Remarkably,
similar results were obtained using CAV1 protector, demonstrat-
ing therefore that miR-199a-5p is a key effector of TGFb response
through CAV1 regulation (Figure 8C, 8D, 8E, 8F and Figure S6).
MiR-199a-5p is dysregulated in mouse models of kidney
and liver fibrosis
A growing body of evidence suggests that miRNAs contribute to
the fibrotic process in various organs such as heart, kidneys, liver
or lungs. For example, previous reports have shown that miR-21
harvested two days after transfection and luciferase activities were analyzed. All renilla luciferase activities were normalized with firefly luciferase
activity. * p,0.05. (C) and (D) Normalized expression values of CAV1 in hFL1 lung fibroblasts after transfection with pre-miR-199a-5p, pre-miR-21 or si-
CAV1 from microarrays (C, n = 2) or real time PCR (D, n = 3) experiments. Data are expressed as mean6 SEM (n= 2). **p,0.01 (E) Western blot analysis
showing the down regulated expression of CAV1 protein after transfection of hFL1 lung fibroblasts with pre-miR-199a-5p, pre-miR-21 or si-CAV1. One
representative experiment out of two is shown.
doi:10.1371/journal.pgen.1003291.g003
Figure 4. TGFb regulates CAV1 by increasing miR-199a-5p expression. MRC-5 lung fibroblasts were treated with 10 ng/mL TGFb for 24 h
and 48 h. MiR-199a-5p (A) and CAV1 expression levels (B) were determined by Taqman PCR. Data are expressed as mean6 SEM. ** p,0.01. (C) CAV1
protein levels were determined by immunoblot analysis. (D) MRC5 cells were transfected with LNA-miR-199a-5p, CAV1 protector or LNA-control then
incubated with or without 10 ng/ml TGFb for 24 h and CAV1 protein levels were determined by immunoblot analysis. Data are representative of
three independent experiments.
doi:10.1371/journal.pgen.1003291.g004
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has an important role in both pulmonary and heart fibrosis
experimental mouse models. Thus, we investigated whether miR-
199a-5p was also dysregulated in other fibrotic tissues, namely
kidney fibrosis and liver fibrosis. To this end, we assessed the
overlap between the miRNA expression profiles corresponding to
three experimental models of fibrosis. Measurements were made
Figure 5. Altered CAV1 expression in bleomycin induced lung fibrosis mouse model. (A) Microarray analysis reveals a significant reduction
of CAV1 expression in C57BL/6 mice treated with bleomycin for 14 days compared with control mice. Data are expressed as mean normalized
fluorescence values 6 SEM (n= 5). ** p,0.01. (B) Real-time PCR was performed to confirm the reduced expression of CAV1 in lungs of C57BL/6 mice
14 days following bleomycin exposure. Data are expressed as mean6 SEM (n= 5). * p,0.05. (C) CAV1 protein expression as detected by immunoblot
analysis in lung tissue samples from C57BL/6 mice treated with bleomycin for 14 days and control mice (n = 3). (D) Immunohistochemical analysis of
CAV1 expression in lung tissue sections from C57BL/6 mice 14 days after bleomycin intra-tracheal instillation. One representative section out of three
is shown.
doi:10.1371/journal.pgen.1003291.g005
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using the same miRNA based platform. We identified 5 miRNAs
commonly dysregulated at a p-value of less than 0.01 (Figure 9A).
Among these miRNAs, 3 were downregulated (miR-193, miR-30b
and miR-29c) and 2 were upregulated (miR-199a-3p and miR-
199a-5p) (Figure 9B).
The enhanced expression of miR-199a-5p was confirmed in two
independent experimental models of liver fibrosis (Figure 10A–
10C) and was correlated with the severity of liver fibrosis, as
BALB/C mice have a more pronounced liver fibrosis than
C57BL/6 mice, following administration of CCL4 (Figure 10A
and 10B). In addition, miR-199a-5p was significantly decreased
during regression of experimental CCL4-induced liver fibrosis
(Figure 10D). Furthermore, we showed that TGFb exposure of
stellate cells was associated with an increase of miR-199a-5p
expression and a decrease of CAV1 expression level (Figure 10E
and 10F). Interestingly, enhanced expression of miR-199a-5p was
also observed in clinical samples from patients with liver fibrosis
(Figure S13).
Similarly, data obtained from the unilateral ureteral obstruction
model of kidney fibrosis showed an enhanced expression of miR-
199a-5p in the injured kidney compared to sham operated mice
(Figure 11A). Interestingly, as for lung fibrosis, kidney expression
of miR-199a-5p was correlated with disease progression. As
depicted in Figure 11B, in situ hybridization performed 28 days
after surgery (i.e. when the fibrosis is established) showed no
detectable signal for miR-199a-5p in normal kidney, whereas the
hybridization signal was greatly enhanced throughout the injured
kidney in area consistent with (myo)fibroblasts. Furthermore,
immunohistochemistry of CAV1 performed on fibrotic kidney
from mice 28 days after surgery showed a marked reduction of
CAV1 in fibrotic area of the kidney (Figure 11C).
Discussion
MiRNA expression profiling using high-throughput genomic
approaches has provided important new insights into the
pathogenesis, classification, diagnosis, stratification, and prognosis
of many human diseases including tissue fibrosis [15,35,36]. In
particular, such approaches have been previously successfully
applied to IPF, revealing miR-21 and let-7d as important
contributors to the lung fibrosis process [13,14]. Our work
represents however, to our knowledge, the first analysis of
miRNAs involved into the differential susceptibility of two murine
strains to bleomycin-induced lung fibrosis. The identification of a
specific miRNA profile associated with bleomycin-sensitive
animals suggests the functional importance of these dysregulated
miRNAs during the pathogenic processes leading to lung fibrosis.
MiR-199a-5p appeared as the most statistically significant and was
well correlated to IPF progression. Thus, altered expression of
miR-199a-5p is likely to represent a primary pathogenic mech-
anism in the development of lung fibrosis rather than a secondary
effect of the long-standing disease process. Other miRNAs
candidates including miR-214, clustered with miR-199a-2 on
mouse chromosome 1 as well as other miRNAs that have been
previously associated to fibrosis, including miR-221-222 and miR-
449a [37,38] also showed an enhanced expression in the lung
fibrosis-susceptible mice. These miRNAs need to be further
analyzed in IPF samples, as previous studies have shown their
implication in the regulation of the stress response or the cell
cycle/apoptosis balance in the epithelial or fibroblast compart-
ment [38–41].
MiR-199a is an evolutionary conserved small RNA initially
identified in the context of inner ear hair cells development and
chondrogenesis [42–44] and numerous reports have now shown its
implication in various tumor types [45–47]. In the context of tissue
fibrosis, both mature forms of miR-199a (i.e., miR-199a-5p and
miR-199a-3p) have been associated with the progression of liver
fibrosis in both humans and mice [48,49]. While our data also
showed an enhanced pulmonary expression of these two miRNAs
in the bleomycin-induced mouse model, expression of miR-199a-
5p was more significant in IPF samples (Table S3 and Figure
S14A). Moreover, our data indicated that miR-199a-3p had
distinct effects on lung fibroblasts differentiation than miR-199-5p,
as assessed by their different impact on aSMA (Figure S14B and
data not shown). This led us to investigate in depth miR-199a-5p
profibrotic effects.
In a recent report describing the miRNA expression profile of
lung fibroblasts, miR-199a-5p was found to be highly expressed
[25]. Our present data establish stromal cells as the primary source
of miR-199a-5p in the injured lungs and also suggests that miR-
199a-5p is involved in the profibrotic effects mediated by
pulmonary fibroblasts. A combination of in silico and experimental
data, described in [25,26,40], identified the transcripts affected by
miR-199a-5p in lung fibroblasts. Functional annotations of the
miR-199a-5p experiments highlighted terms such as ‘‘Integrin
Signaling’’ and ‘‘Caveolar-mediated Endocytosis Signaling’’.
Among the set of transcripts that were down-regulated after
ectopic expression of miR-199a-5p, we then restricted our work to
a group of 21 miR-199a-5p target genes predicted by 3
independent algorithms, showing the largest modulation factors
and smallest statistical p-values. This short list included CAV1, a
structural component of caveolae, previously associated with lung
fibrosis [14,18,19].
Caveolae refer to 50–100 nanometers small bulb-shaped
invaginations of the plasma membrane. They exert major
biological functions in numerous cellular processes such as
membrane trafficking or cell signaling [50]. CAV1 and CAV2,
the main coat proteins of caveolae, are relatively highly expressed
in endothelial cells and fibroblasts of pulmonary origin [51].
Caveolae role is particularly important in the context of TGFb
signaling. Whereas TGFb receptor endocytosis via clathrin-coated
pit-dependent internalization promotes TGFb signaling, the lipid
raft-caveolar internalization pathway facilitates the degradation of
TGFb receptors, therefore decreasing TGFb signaling [52].
Previous studies have shown that a reduced CAV1 expression in
lung fibroblasts contributes to IPF pathogenesis by promoting
TGFb profibrotic effects [19]. In line with this, we provide
evidence that miR-199a-5p can directly repress CAV1 in lung
fibroblasts, thereby stimulating their proliferation, migration,
invasion and differentiation into myofibroblasts (Figure 12).
Additionally, we showed in a large cohort of IPF patients an
enhanced expression of miR-199a-5p that was reproduced in three
independent mouse models of fibrosis as well as a decreased
Figure 6. miR-199a-5p and its target CAV1 are dysregulated in IPF. (A,B) Box plots showing the normalized expression of log2-transformed
CAV1 and miR-199a-5p in both IPF (n = 94) and control (n = 83) lungs. The box represents the 25–75% quartiles, the line in the box represents the
median and whiskers represent the range. (**p,0.001). (C) Immunohistochemical analysis of CAV1 expression in lung tissue sections from IPF
patients (i, ii and iii) and normal lung (iv). Three representative sections are shown (IPF n= 8 and control n = 8). (D) In situ hybridization (ISH) was
performed to determine the localization of miR-199a-5p in lung tissue of IPF patients (i, ii and iii). ISH with scrambled probes (iv). Three representative
sections are shown (n= 6).
doi:10.1371/journal.pgen.1003291.g006
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Figure 7. Functional impact of miR-199a-5p on lung fibroblasts. Increased expression of miR-199a-5p in lung fibroblasts results in an
enhanced ability of fibroblasts to migrate, invade matrigel, proliferate and differentiate into myofibroblasts. Lung fibroblasts were transfected with
10 nM of miR-199a-5p mimic or control. (A,B) In vitro scratch assay was performed to assess the rate of migration of A significant increase (p,0.01) in
the migration rate was observed in miR-199a-5p transfected hFL1 lung fibroblasts compared with control. Data are representative of two
independent experiments. (C) Invasion assay on matrigel showing that overexpression of miR-199a-5p increases MRC5 lung fibroblast invasiveness..
Data are representative of two independent experiments. (D) Proliferation assay was performed by bivariate flow cytometric analysis of EdU/DNA-
stained MRC5 cells. The x-axis represents the linear intensity obtained from propidium iodide (total DNA content), and the y-axis represents the
logarithmic intensity obtained from the Alexa Fluor 647. Cells are separated into G0/G1 phase and G2/M phase according to their DNA content, and
into labeled undivided and labeled divided subgroups according to the DNA content of EdU-labeled cells. The % of cells in S phase is indicated on the
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expression of CAV1. Finally, in contrast to a recent report showing
that miR-199a-5p, by targeting SMAD4, inhibited TGFb-induced
gastric cancer cell growth [53], we found that lung fibroblasts
overexpressing miR-199a-5p have an increased SMAD4 expres-
sion (Figure S14B), suggesting thus a potential opposite function of
this miRNA between epithelial and mesenchymal cells.
MiRNAs, by affecting the expression of multiple genes, can act
as master regulators of complex biological processes and aberrant
expression of miRNA is known to have a profound impact on
various distinct biological pathways. Thus, the elucidation of the
critical genes and relevant pathways/networks modulated by
miRNAs is important to understand the mechanisms by which
miRNAs exert their pathogenic effects. Our systematic analysis of
the gene expression profiles of lung fibroblasts overexpressing
miR-199a-5p led to the identification of a large number of
transcripts that were significantly modulated by this miRNA.
These experiments have established that miR-199a-5p is directly
or indirectly involved in the regulation of genes previously
associated with lung fibrosis: CCL2, a potent mononuclear cell
chemoattractant, PLAU [54], a component of the fibrinolysis
system, TGFBRI, the TGFb receptor type I [55], MMP3 [56] and
CAV2 [57]. Interestingly, these regulations were independent of
CAV1 targeting, suggesting therefore that miR-199a-5p modu-
lates the expression of several components of various distinct
biological pathways to elicit, in lung fibroblasts, a profibrotic
response.
Before this study, miR-21 was clearly established as an effector
of TGFb signaling, able to promote fibroblast proliferation and
differentiation into myofibroblasts [58]. In the context of lung
fibrosis, miR-21 has been described to mediate lung fibroblast
activation and fibrosis [14]. MiR-199a-5p and miR-21 exert
indeed similar pro-fibrotic effects on lung fibroblasts. This is
further demonstrated by overexpression of miR-21 and miR-199a-
5p, which induce lung fibroblast migration to a similar extent
(Figure S15). Interestingly, while both miRNAs appear as TGFb
effectors, the comparison of their associated gene expression
signature indicated a limited overlap (Figure 2A). Moreover,
CAV1 expression is unaffected by overexpression of miR-21 in
lung fibroblasts, suggesting that both miRNAs, in response to
TGFb, modulate distinct signaling pathways to produce cooper-
ative effects involved in fibroblast activation.
The mechanisms involved in the TGFb-dependent modulation
of miR-21 and miR-199a-5p are also of particular interest. While
both miR-21 and miR-199a-5p have been shown to be regulated
by TGFb, their expression may be primarily regulated through a
Smad-dependent post-transcriptional mechanism promoting
miRNA maturation by Drosha [59,60]. Our data showing that
both pri-miRNA-199a1 and pri-miRNA-199a2 are significantly
upregulated in bleomycin-treated mice (Figure S2B) and TGFb-
stimulated fibroblasts (Figure S16) suggest that additional TGFb-
dependent transcriptional regulations occur that will need to be
more fully analyzed.
Finally, our observation that miR-199a-5p is also dysregulated
in two additional experimental models of tissue fibrosis (i.e. kidney
fibrosis and liver fibrosis) establishes miR-199a-5p as a ubiquitous
factor associated with tissue fibrogenesis. The recently reported
association of CAV1 with kidney fibrosis [61,62], together with the
exclusive distributions of miR-199a-5p and CAV1 in the injured
kidney, leads us to hypothesize that miR-199a-5p also controls
CAV1 expression in kidney, thus contributing to kidney fibrosis.
Further information came from the liver fibrosis model. As liver
fibrosis can regress after cessation of the triggering injury, even at
advanced fibrotic stages [63], the decrease of miR-199a-5p
observed during resolution of liver fibrosis sets for the first time
a specific miRNA as an important player for orchestrating the
molecular events occurring during regression of liver fibrosis.
Importantly, this implies that therapeutic strategies based on
modulation of miRNAs have a potential to prevent liver fibrosis
progression but also to resolve liver fibrosis.
In conclusion, the results of this study further underline the
pivotal roles played by specific miRNAs in mediating changes in
gene expression and cell functions occurring during pulmonary
fibrosis. In particular, our results identified miR-199a-5p as a new
determinant of tissue fibrosis. We thus anticipate that strategies
preventing the up-regulation of miR-199a-5p may represent a new
effective therapeutic option to treat fibroproliferative diseases.
Methods
Cell lines, reagents, and antibodies
Human normal pulmonary fibroblasts MRC-5 (CCL-171) and
hFL1 (CCL-153), human lung cancer cell line A549 (CCL-185)
and HEK-293 (CRL-1573) cells were purchased from the
American Type Culture Collection (ATCC, Manassas, VA,
USA), frozen at an early passage and each vial used for
experiments was cultured for a limited number of passages (,8).
For maintenance, cells were cultured in the appropriate medium
(MEM for MRC-5, F12-K for hFL1 and A549, DMEM for HEK-
293) containing 10% fetal calf serum (FCS), at 37uC with 5% v/v
CO2. Recombinant TGFb was purchased from Sigma-Aldrich.
The following monoclonal (mAbs) and polyclonal (pAbs) Antibod-
ies were used: rabbit anti-CAV1 pAbs (sc-894, Santa Cruz
Biotechnology Inc.), rabbit anti-SMAD4 (9515) and anti- b-Actin
(13E5) mAbs (Cell Signalling), mouse anti- aSMA mAbs (1A4,
Dako) for immunohistochemistry and (4A8-2H3, Abnova) for
Western Blot and immunocytofluorescence.
Animal treatment
All animal care and experimental protocols were conducted
according to European, national and institutional regulations.
Personnel from the laboratory carried out all experimental
protocols under strict guidelines to insure careful and consistent
handling of the mice.
Mouse model of lung fibrosis. 9–12 weeks old male
C57BL/6 and BALB/C mice were purchased from Charles
River, France. To induce fibrotic changes, mice were intratrache-
ally instillated with bleomycin or PBS as previously described
[25,64]. Briefly, mice were anesthetized with sevoflurane inhala-
tion (Abbott) and placed in dorsal recumbency. Transtracheal
insertion of a 24-G animal feeding needle was used to instillate
bleomycin (0.75 unit/ml) or vehicle (PBS), in a volume of 80 ml.
Mice were sacrificed 7 and 14 days after instillation and lungs were
removed for further analysis. Expression analyses were performed
on 5 mice per group except for the miRNA microarray
upper right panel. One representative experiment out of three is shown. (E) Confocal microscopy of MRC5 cells overexpressing miR-199a-5p revealed
that increasing miR-199a-5p levels in lung fibroblasts promotes their differentiation into myofibroblasts. Cells were stained with an antibody against
a-SMA (green) and phalloidin (red). Experiments were performed twice. (F) Relative expression of COL1A1 was assessed by Taqman PCR in MRC5 cells
overexpressing miR-199a-5p and exposed or not to TGFb. Data are expressed as mean 6 SEM and derived from 2 independent experiments.
*p,0.05.
doi:10.1371/journal.pgen.1003291.g007
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experiment where 3 mice per group were used. Histological
analyses and western blot were performed on 3 C57BL/6 mice.
Mouse model of kidney fibrosis. 9–12 weeks old male
C57BL/6 mice were purchased from Charles River, France. Mice
underwent anesthesia by intraperitoneal injection of pentobarbital
(50 mg/kg body wt). After a standard laparotomy, the left
proximal ureter was exposed and ligatured with 4-0 silk at two
points. The sham operation consisted of a similar identification of
the left ureter, but ligature of the ureter was not performed.
Expression analyses were performed on 4 to 7 mice per group. For
the histological analyses, 2 to 3 mice were used.
Mouse model of liver fibrosis. 6–8 weeks old male C57BL/
6 and BALB/C mice were purchased from Jackson laboratory (Bar
Harbor). To induce liver fibrosis, mice received 0.6 ml/kg body
weight of CCl4 (Merck) mixed with corn oil (Sigma life science)
intraperitoneally as previously described [65]. Bile duct ligation
(BDL) was performed by exposing the common biliary duct and
double-ligaturing it, then cutting through between the ligations as
described in [65]. For fibrosis regression mice were treated for 6
weeks with CCl4 as described above and sacrificed 2 or 4 weeks
respectively after the end of treatment. For CCl4 induced liver
fibrosis mouse model, expression analyses were performed on 5
mice whereas 4 mice were used for bile duct ligation.
Isolation of primary stellate cells
Primary stellate cells were isolated from C57BL/6 mice at the
age of 40 to 55 weeks and stimulated with 20 ng/ml of TGF-ß
(Sigma Aldrich) for 48 h as previously described [65].
Human lung tissue
Flash frozen lung tissue from 94 human subjects with IPF and
83 control subjects with no chronic lung disease were obtained
from the Lung Tissue Research Consortium (LTRC). These
diagnoses were made using ATS/ERS guidelines [66,67] from
review of clinical history, pathology, and radiology. All exper-
iments were approved by the local Institutional Review Board at
the University of Pittsburgh (IRB# 0411036). Clinical data were
made entirely available to the investigators for review.
Paraffin lung sections from patients with IPF were obtained
from Lille’s Hospital. Experiments were approved by the
institutional review board of Lille’s Hospital.
Histopathology
Kidneys and lungs were fixed overnight with neutral buffered
formalin and then embedded in paraffin. Five-micrometer-thick
sections were mounted and stained with hematoxylin and eosin as
well as Masson’s trichrome to assess the degree of fibrosis.
Histologic sections were reviewed by an experienced pathologist.
RNA isolation
Total RNA were extracted from lung tissue and cell samples
with TRIzol solution (Invitrogen). Integrity of RNA was assessed
by using an Agilent BioAnalyser 2100 (Agilent Technologies) (RIN
above 7).
Microarrays
MiRNA microarrays of mice lungs. The oligonucleotide
sequences corresponding to 2054 mature miRNAs found in the
miRNA registry (Release 8.2 [68]) are available on http://www.
microarray.fr:8080/merge/index (follow the link to ‘‘microRNA’’:
platform referenced in GEO as GPL4718). Three biological
replicates were performed for each comparison. The experimental
data and microarray design have been deposited in the NCBI
Gene Expression Omnibus (GEO) (http://www.ncbi.nlm.nih.
gov/geo/) under serie GSE34812. The experimental design used
a dye-swap approach, so that each mouse probe, printed 8 times
on the microarray was measured independently 16 times for each
sample. Target preparation and array hybridization were
performed as previously described [24–26].
MiRNA microarray analysis of human lungs. A micro-
RNA microarray analysis was done as previously described by us
[13]. Briefly, 100 ng of total RNA was labeled and hybridized
onto the Agilent microRNA Microarray Release 16.0, 8660K.
After washing, the arrays were scanned using the Agilent
Microarray Scanner. The scanned images were processed by
Agilent’s Feature Extraction software version 9.5.3. MicroRNA
microarray data analysis was done using GeneSpring v11.5 and
BRB-ArrayTools v4.1 developed by Dr. Richard Simon and the
BRB-ArrayTools Development Team. The data were quantile
normalized. MicroRNA microarray data are publically available
through the Lung Genomics Research Consortium (LGRC)
website (lung-genomics.org).
Expression microarrays. For gene expression arrays RNA
samples were labeled with Cy3 dye using the low RNA input
QuickAmp kit (Agilent) as recommended by the supplier. 825 ng of
labeled cRNA probe were hybridized on 8660K high density
SurePrint G3 gene expression mouse or human Agilent micro-
arrays. Two (human in vitro experiments) or five (in vivo-derived
samples) biological replicates were performed for each comparison.
The experimental data have been deposited in the NCBI Gene
Expression Omnibus (GEO) (http://www.ncbi.nlm.nih.gov/geo/)
under SuperSerie record GSE34818 (series GSE34812 and
GSE34814 for miRNA and mRNAs responses to bleomycin
instillation, respectively; serie GSE34815 for miRNA/siRNA
transfection experiments in human fibroblasts hFL1). For the
human gene expression arrays, the data was log2 transformed and
normalized using a cyclic loess algorithm in the R programming
environment as previously described [69]. The human microarray
Figure 8. miR-199a-5p is an effector of the TGFb pathway. (A) Heatmap of significant canonical pathways associated with miR-199a-5p, miR-
21 and siCAV1 conditions identified through Ingenuity Pathway Analysis. (B) Gene Set enrichment analysis plots for an experimental TGFb-signature
showing significant enrichment for miR-199a-5p up- and down-regulated genes. Data were treated according to Gene Set Enrichment Analysis
(GSEA) software, with transcripts being ordered according to miR-199a-5p versus miR-Neg conditions scaled by their standard deviation. Up- and
Down-regulated genes were run separately against an experimental TGFb signature obtained in the same cellular models (hFL1 fibroblasts treated
with 10 ng/ml TGFb during 48 h): 2 sets of 134 and 113 genes corresponding to TGFb up- and down-regulated gene sets have been selected as
described in the Materials and Method section (p,0.05). In each case, graphs show the enrichment plot, the score at the peak corresponding to the
ES and the position of the TGFb gene set in the ranked list of genes (each transcript indicated by a vertical bar. (C) MRC5 cells were transfected with
LNA-miR-199a-5p, CAV1 protector or LNA-control, then incubated with or without 10 ng/ml TGFb for 24 h and cells were stained with an antibody
against a-SMA (green), phalloidin (red) and DAPI (blue). Experiments were performed twice. (D) Cells were co-transfected with SMAD-luciferase
reporter plasmid, luciferase activities were analyzed 48 h after transfection. All firefly luciferase activities were normalized with renilla luciferase
activity. * p,0.05. Two independent experiments. (E) and (F) In vitro scratch assay was performed to assess the migration rate of TGFb-stimulated
hFL1 lung fibroblasts treated with LNA-anti-miR-199a-5p, LNA-control inhibitor and CAV1 protector. A significant decrease (p,0.01) in the migration
rate was observed in both LNA-anti-miR-199a-5p and CAV1 protector transfected lung fibroblasts compared with control. Data are representative of
two independent experiments.
doi:10.1371/journal.pgen.1003291.g008
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data has been made available at the LTRC (ltrcpublic.org) and the
LGRC websites as part of the LTRC protocol.
Statistical analysis and biological theme analysis. Norma-
lization was performed using the Limma package available from
Bioconductor (http://www.bioconductor.org). Intra slide (for 2 colours
dye-swap experiments only) and inter slide normalization was
performed using the Print Tip Loess and the quantile methods,
respectively. Means of ratios from all comparisons were calculated and
B test analysis was performed. Differentially expressed genes were
selected using Benjamini-Hochberg correction of the p-value for
multiple tests, based on a p-value below 0.05. Data from expression
microarrays were analyzed for enrichment in biological themes (Gene
Ontology molecular function and canonical pathways) and build
biological networks built using Ingenuity Pathway Analysis software
(http://www.ingenuity.com/) andMediante (http://www.microarray.
fr:8080/merge/index) [70], an information system containing diverse
information about probes and data sets. Gene Set Enrichment Analysis
(GSEA) was used to determine whether an a-priori defined set of genes
can characterize differences between two biological states [34,71].
Hierarchical clusterings were done with the MultiExperiment Viewer
Figure 9. MiR-199a-5p is commonly dysregulated in three experimental mouse models of liver, lung, and kidney fibrosis. (A) Venn
diagram showing the relationships of miRNA expression changes in lungs from C57BL/6 14 days after Bleomycin treatment (n = 4 mice), livers from
BALB/C mice 6 weeks after CCl4 administration (n = 5 mice) and kidneys from C57BL/6 mice 28 days following unilateral ureteral obstruction (n = 4
mice). The numbers of miRNAs whose expression was differentially detected in each mouse model at p,0.01 are shown. Data on liver fibrosis are
from (17). (B) List of the 5 miRNAs dysregulated in the three experimental models of fibrosis. ttest, p,0.01.
doi:10.1371/journal.pgen.1003291.g009
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Figure 10. Altered expression of miR-199a-5p in CCl4 induced liver fibrosis mouse model. (A) Expression of miR-199a-5p in livers from 6
weeks CCl4-treated or oil-treated BALB/C mice was analyzed by qPCR; n = 5 per group. Data are expressed as mean 6 SEM. ** p,0.01. (B) Expression
of miR-199a-5p in livers from 6 weeks CCl4-treated or oil-treated C57BL/6 mice was analyzed by qPCR; n = 5 mice per group. Data are expressed as
mean 6 SEM. * p,0.05. (C) Expression of miR-199a-5p in livers from C57BL/6 mice 21 days following bile duct ligation or sham operation was
analyzed by qPCR; n = 4 mice per group. Data are expressed as mean6 SEM. * p,0.05. (D) Expression of miR-199a-5p in liver of C57BL/6 mice during
fibrosis regression. Liver fibrosis was induced by injection of CCl4 and expression of miR-199a-5p was assessed 6 weeks after CCl4 treatment as well as
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2 and 4 weeks after the last injection. Data are expressed as mean 6 SEM. * p,0.05; Expression of miR-199a-5p (E) and CAV1 (F) in primary stellate
cells isolated from C57BL/6 mice and stimulated with 20 ng/ml TGFß for 48 h.
doi:10.1371/journal.pgen.1003291.g010
Figure 11. Altered expression of miR-199a-5p and CAV1 in the unilateral ureteral obstruction (UUO) mouse model of kidney
fibrosis. (A) miR-199a-5p expression in kidney from C57BL/6 mice after UUO at the indicated time points. n = 5 to 7 mice in each group. Data are
expressed as mean 6 SEM. * p,0.05 and ** p,0.01. (B) Paraffin sections were prepared from kidneys of C57BL/6 mice harvested 28 days after UUO.
In situ hybridization assay was performed to determine the localization of miR-199a-5p in the kidney. Results represent one out of three independent
experiments. (C) Immunohistochemical analysis of CAV1 expression in kidney tissue sections from C57BL/6 mice 28 days after UUO. One
representative section out of two is shown.
doi:10.1371/journal.pgen.1003291.g011
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Figure 12. Proposed model of miR-199a-5p profibrotic function in lung fibrogenesis. Persistent injury of the respiratory epithelium causes
release of profibrotic factors such as TGFb. In lung fibroblasts, TGFb binds to TGFbR I (RI) and II (RII) and the resultant complex can be internalized via
two distinct endocytic pathways. The clathrin-coated pit pathway (red arrows) increases TGFb signal transduction leading to the activation of lung
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(MeV) program version 4.3, using a Manhattan distance metric and
average linkage.
MiRNA targets analysis. MiRonTop [29] is an online java
web tool (available at http://www.microarray.fr:8080/miRonTop/
index) that integrates DNA microarrays data to identify the
potential implication of miRNAs on a specific biological system.
Briefly, MiRonTop ranks the transcripts into 2 categories
(‘Upregulated’ and ‘Downregulated’), according to thresholds for
expression level and for differential expression. It then calculates the
number of predicted targets for each miRNA, according to the
prediction software selected (Targetscan, MiRBase, PicTar, exact
seed search: 2–7 or 1–8 first nucleotides of the miRNA, TarBase v1),
in each set of genes. Enrichment in miRNA targets in each category
is then tested using the hypergeometric function. The absence of
siRNA off-target effect was checked in si-CAV1 transcriptome
experiments using the Sylamer Tool [72].
Transfection and luciferase assays
Pre-miRNAs, LNA-based miRNA inhibitors, target site
blocker, and siRNAs transfection in lung fibroblasts. Pre-
miR-199a-5p, pre-miR-21 and control miRNA (miR-Neg # 1)
were purchased from Ambion. For miR-199a-5p knockdown and
target site blocker experiments, anti-miR-199a-5p LNA, negative
control anti-miR-159s LNA (miRCURY LNA Knockdown
probes) and CAV1 protector were ordered from Exiqon. Si-
RNA directed against CAV1 and control siRNA (Silencer Select
validated siRNAs) were from Applied Biosystems. MRC5/hFL1
cells were grown in 10% FCS in DMEM and transfected at 30 to
40% confluency in 6- 12- or 96 well plates using Lipofectamin
RNAi MAXTM (Invitrogen) with pre-miRNA, siRNAs LNA
inhibitors and CAV1 protector at a final concentration of
10 nM unless indicated.
Pre-miRNAs and psiCHECK-2 plasmid constructs co-
transfection. Molecular constructs were made in psiCHECK-2
(Promega) by cloning behind the Renilla luciferase in the XhoI
and NotI restrictions sites, annealed oligonucleotides derived from
the CAV1 39 UTR described below. Mutated nucleotides located
in the miR-199a-5p-binding site are underlined. HEK293 cells
were plated into 96-well and cotransfected using lipofectamin 2000
(Invitrogen) with 0.2 mg of psiCHECK-2 plasmid construct and
pre-miR-199a-5p or control miRNA at different concentrations.
48 hours after transfection, Firefly and Renilla Luciferase activities
were measured using the Dual-Glo Luciferase assay (Promega).
hsa-CAV1: WT (sense):
TCGAGGACACTTTAATTACCAACCTGTTACCTACTT-
TGACTTTTTGCATTTAAAACAGACACTGGCATGGATA-
TAGTTTTACTTTTAAACTGTGTACGC
hsa-CAV1: WT (reverse):
GGCCGCGTACACAGTTTAAAAGTAAAACTATATCCA-
TGCCAGTGTCTGTTTTAAATGCAAAAAGTCAAAGTAG-
GTAACAGGTTGGTAATTAAAGTGTCC
hsa-CAV1: MUT (sense):
TCGAGGACACTTTAATTACCAACCTGTTACCTACTT-
TGACTTTTTGCATTTAAAACAGAGAGTCGCATGGATA-
TAGTTTTACTTTTAAACTGTGTACGC
hsa-CAV1: MUT (reverse):
GGCCGCGTACACAGTTTAAAAGTAAAACTATATCCA-
TGCGACTCTCTGTTTTAAATGCAAAAAGTCAAAGTAG-
GTAACAGGTTGGTAATTAAAGTGTCC
Smad reporter assay. MRC5 cells were seeded in 96 well
plate and cotransfected 24 h later at 40% confluency using RNAi
MAX lipofectamine reagent with 100 ng SMAD reporter vector
(Cignal Smad reporter,- QIAGEN) and 10 nM LNA-control,
LNA-199a-5p or CAV1 protector. Twenty four hours after
transfection, cells were serum starved 3 h before adding 10 ng/
ml TGFb. Cells were lyzed and Glo luciferase assay (Promega) was
performed 24 h following TGFb exposure.
Quantitative RT–PCR
Mature miRNA expression. MiR-199a-5p expression was
evaluated using TaqMan MicroRNA Assay (Applied Biosystems)
as specified in their protocol. Real-time PCR was performed using
Universal Master Mix (Applied Biosystems) and ABI 7900HT
real-time PCR machine. Expression levels of mature microRNAs
were evaluated using comparative CT method (22deltaCT).
Pri-miRNA expression. Pri-miR-199a-1 and pri-miR-199a-
2 expression were evaluated using TaqMan pri-microRNA Assay
(Applied Biosystems) following manufacturer’s recommandations.
Real-time PCR was performed using TaqMan gene expression
Master Mix (Applied Biosystems) and ABI 7900HT real-time PCR
machine. Expression levels of pri-miRNAs were evaluated using
comparative CT method (22deltaCT).
Gene expression. Expression levels of both human and
mouse CAV1, human COL1A1 were analyzed using TaqMan
MicroRNA Assay (Applied Biosystems) according to the manu-
facturer’s instructions. Real-time PCR was performed using
TaqMan Gene Expression Master Mix (Applied Biosystems) and
ABI 7900HT real-time PCR machine. Expression levels were
evaluated using comparative CT method (22deltaCT). For
normalization, transcript levels of RNU44 (human samples) and
sno202 (mouse samples) were used as endogenous control for
miRNA real time PCR. Transcript levels of PPIA (human and
mouse samples) were used as endogenous control for gene/pri-
miRNA expression.
Protein extraction and immunoblotting
Cells or tissues were lysed in lysis buffer (M-PER protein
extraction reagent for cells, T-PER protein extraction reagent
for tissues) and protease inhibitors cocktail (Pierce). The
lysates were quantified for protein concentrations using the
Bradford assay (Biorad). Proteins (10 mg per sample) were
separated by SDS-polyacrylamide gel and transferred onto
nitrocellulose membranes (GE Healthcare). The membranes
were blocked with 5% fat free milk in Tris-buffered saline
(TBS) containing 0.1% Tween-20 (TBS-T) and subsequently
incubated with CAV1, a-SMA or b-actin primary antibodies
overnight at 4uC. After washing with TBS-T for 30 minutes at
room temperature, the membrane was further incubated with
horseradish peroxidase–conjugated secondary antibodies for
1.5 hours, followed by 30 minutes of washing with TBS-T.
Protein bands were visualized with Amersham ECL substrates
(GE Healthcare).
fibroblasts and ultimately lung fibrosis whereas the CAV1 lipid raft pathway (green arrows) mediates TGFb/TGFbR complex degradation, thus
decreasing TGFb signaling and preventing lung fibrosis [73]. Production of miR-199a-5p in response to TGFb in lung fibroblasts results in CAV1
downregulation and subsequently, impaired TGFb/TGFbR complex degradation. This miRNA-mediated mechanism for low CAV1 expression
promotes TGFb signaling and the pathogenic activation of lung fibroblasts. CAV1 = caveolin-1, TGFb= Transforming Growth factor-b,
TGFbR= Transforming Growth factor-b Receptor, SBE = SMAD Binding Element, ECM= Extracellular Matrix.
doi:10.1371/journal.pgen.1003291.g012
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Immunohistochemistry
Five-mm paraffin-embedded sections were sequentially incubated in
xylene (5 minutes twice), 100% ethyl alcohol (5 minutes twice), 95%
ethyl alcohol (5 minutes twice), and 80% ethyl alcohol (5 minutes).
After washing with water, the sections were antigen-retrieved using
citrate buffer (pH 6.0; DAKO) in a steamer for 20 minutes and cooled
to ambient temperature. Sections were then washed with TBS-T and
quenched with 3% hydrogen peroxide in TBS for 10 minutes, blocked
for avidin/biotin activity, blocked with serum-free blocking reagent,
and incubated with primary antibody as follows: for CAV1 staining,
sections were incubated with antibody for 1 hour at ambient
temperature; for alpha-SMA staining, sections were incubated with
antibody overnight at 4uC. Immunohistochemical staining was
developed using the DAB substrate system (DAKO).
In situ hybridization
In situ hybridization of miR-199a-5p was performed using
double DIG-labeled LNA probes (Exiqon, Woburn, MA).
Paraffin-embedded mouse tissues were dewaxed in xylene and
rehydrated in descending grades of alcohol. The slides were then
washed in PBS (pH 7.5) and permeabilized by incubating for
15 min in proteinase K (Ambion) for 15 min at 37uC. The slides
were again washed in PBS, and prehybridized in hybridization
buffer (50% formamide, 56SSC, 0.1% Tween-20, 9.2 mM citric
acid, 50 mg/ml heparin, and 500 mg/ml yeast RNA, pH 6) in a
humidified chamber. The double DIG-labeled LNA probes were
then added to the sections at a 80 nM concentration and
incubated 2 hours at 50uC in a humidified chamber. The slides
were rinsed in 56 SSC, 16 SSC and 0.26 SSC solutions at the
same hybridization temperature. This step was followed by
blocking with 2% sheep serum, 2 mg/ml BSA in PBS+0.1%
Tween-20 (PBST) and incubation with anti-DIG-AP Fab
fragments antibody (1:800) (Roche Applied Sciences) for 2 hours
at room temperature. After washing in PBST, the color reaction
was carried out by incubation in 5-bromo-4-chloro-3-indolyl
phosphate (BCIP)/nitro blue tetrazolium (NBT) color solution
(Roche Applied Sciences) with 1 mM levamisole overnight at
room temperature. The color reaction was stopped after
observation of sufficient development of blue precipitate by
washing with PBST. The slides were then counterstained with
Fastred (Sigma Aldrich), mounted and coverslipped.
Immunofluorescence analysis
MRC5 cells were grown on a Round Glass Coverslips Ø
16 mm (thermo scientific) placed inside a 12 Multiwell Plate.
Coverslips slides were washed in phosphate-buffered saline and
fixed in 4% paraformaldehyde for 15 min, cells were then
permeated using 0.1% Triton X-102 (Agilent Technologies) for
10 min. and blocked with PBS solution containing BSA (3%) for
30 min. Incubation with primary antibodies was performed in a
bloking solution BSA (1%) at 37uC for 1 h at the following
dilutions; a-SMA (1:1000), CAV1 (1:50),. After three washes with
PBS, cells were incubated with secondary Alexa Fluor 488 goat
anti-Mouse IgG (Invitrogen) (1:500), Alexa Fluor 647 goat anti-
rabbit IgG (Invitrogen) (1:500) and Alexa Fluor 647 Phalloidin
(A22287 - Life technologies) (1Unit/slide). Fourty five min later,
Coverslips slides were fixed on microscope slides using ProLong
Gold Antifade Reagent with DAPI (Invitrogen). Fluorescence was
viewed with an FV10i Olympus confocal scanning microscope.
Cell proliferation assay
MRC5 cells (150,000/well) were seeded in duplicate in DMEM
supplemented with 10% FBS on 60-mm cell culture dishes. Cells
were serum starved the next day and transfected with pre-miR-
199a-5p at 10 nM. Cell proliferation was assessed 48 h after
transfection by flow cytometry using the click-iT EdU cell
proliferation assay (Invitrogen) according to the manufacturer’s
instructions.
In vitro wound healing assay
hFL1 cells were seeded on Type-I collagen coated 12-well plates
and transfected as described above. Forty eight hours after
transfection, confluent cells were (FCS) starved 3 h before adding
10 ng/ml TGFb and wounded using a pipet tip. The in vitro
wound-healing process was then recorded by videomicroscopy for
24 h from then scratching on an Axiovert 200 M inverted
microscope (Carl Zeiss) equipped with 37uC and 5% CO2
regulated insert (Pecon GmbH). Brightfied images were taken each
30 min through a 106 phase contrast objective with a Cool-
SNAPHQ CCD Camera managed by Metamorph Software
(Roper Scientific). The motility of the cells was assessed by
evaluating the repaired area percentage using ImageJ sotware.
Invasion assay
Invasion of MRC5 fibroblast overexpressing miR-199a-5p was
assessed using commercially available 24-well BioCoat Matrigel
Invasion Chamber (BD Biosciences). In brief, pulmonary fibro-
blasts were transfected either with pre-miR-199a-5p or negative
control as described above. Twenty four hours after transfection,
cells were harvested with trypsin-EDTA, centrifuged, and
resuspended in DMEM medium. Cell suspensions (16105 cells/
well) were added to the upper chamber. Bottom wells of the
chamber were filled with DMEM medium containing 10% FBS as
chemoattractant, whereas the upper chamber was filled with
DMEM only. After incubation for 48 h at 37uC, the non-invading
cells on the top of the membrane were removed with a cotton
swab. Membrane containing invading-cells were fixed with
methanol, washed three times with PBS and mounted with DAPI
hard set (Vector Laboratories) onto glass slides for fluorescent
microscopy.
Statistical analysis
Results are given as mean6S.E.M. Statistical analyses were
performed by using Student’s t-test as provided by Microsoft
Excel.
Supporting Information
Figure S1 Study schema.
(TIF)
Figure S2 miR-199a-5p and pri-miR-199a expression in
C57BL/6 mice 14 days following bleomycin exposure. (A) Real-
time PCR was performed to confirm the enhanced expression of
miR-199a-5p in lungs of C57BL/6 and BALB/C mice 14 days
following bleomycin exposure on an independent set of mice (n = 5
mice in each group). Data are expressed as mean 6 SEM.
*p,0.05. (B) Pri-miR-199a-1 and pri-miR-199a-2 gene expression
in lungs from C57BL/6 mice 14 days after bleomycin instillation.
n = 5 mice in each group, data are expressed as mean 6 SEM.
*p,0.05 and **p,0.01.
(TIF)
Figure S3 miR-21 expression during bleomycin induced lung
fibrosis. (A) Normalized fluorescence expression values of miR-21
in lungs from Balb/c and C57BL/6 mice in response to bleomycin
at the indicated time points from microarrays experiments (n = 3).
Data are expressed as mean 6 SEM. **p,0.01 (B) Real-time
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PCR was performed to confirm the enhanced expression of miR-
21 in lungs of C57BL/6 and BALB/c mice 14 days following
bleomycin exposure. n= 5 mice in each group, data are expressed
as mean 6 SEM. ** p,0.01. (C) Paraffin sections were prepared
from C57BL/6 mice harvested 14 days following bleomycin intra-
tracheal instillation. In situ hybridization was performed to show
the localization of miR-21 in fibrotic area of the lungs (i–iv).
Results represent one out of three independently performed
experiments.
(TIF)
Figure S4 CAV1 is a direct target of miR-199a-5p. Co-
transfection of pre-miR-199a-5p or pre-miR-Neg and human
CAV1 39UTR-derived psiCHECK-2 construct in A549 cells show
a significant decrease in normalized luciferase activity 48 h post-
transfection. * p,0.05.
(TIF)
Figure S5 Decreased CAV1 expression after transfection of
MRC5 lung fibroblasts with pre-miR-199a-5p. (A) MRC5 Lung
fibroblasts that were transfected with 10 nM of pre-miR-199a-5p
for 48 h show a significant decrease in CAV1 expression as
determined by real-time PCR. Data are expressed as mean 6
SEM. **p,0.01. (B) Western blot analysis showing the downreg-
ulated expression of CAV1 protein after transfection of MRC-5
lung fibroblasts with pre-miR-199a-5p. Data are representative of
two independent experiments.
(TIF)
Figure S6 MiR-199a-5p mediates TGFb dependent differenti-
ation of lung fibroblast into myofibroblasts through CAV1
regulation. Normal human pulmonary fibroblasts MRC5 were
transfected with a control LNA inhibitor (LNA-CT), a LNA-miR-
199a-5p inhibitor or a target site blocker directed against CAV1 3-
UTR (CAV1 protector) (n = 2). Protein samples were harvested at
48 h post-transfection and analyzed by western Blot for CAV1
and aSMA.
(TIF)
Figure S7 Pulmonary expression of CAV1 in BALB/c mice 14
days after bleomycin injection. Real-time PCR was performed to
assess the expression of CAV1 in lungs of BALB/c mice 14 days
following bleomycin exposure. n= 5 mice in each group, data are
expressed as mean 6 SEM. n.s. = non significant.
(TIF)
Figure S8 MiR-199a-5p expression determined by qPCR using
FFPE lung samples. Box plot showing the increased expression of
miR-199a-5p in IPF samples (n = 10) compared to control (n = 10).
Significance was evaluated using the Kruskal–Wallis rank-sum
test. The box represents the 25–75% quartiles, the line in the box
represents the median and whiskers represent the range.
(TIF)
Figure S9 Expression of ACTA2 and PPARG following overex-
pression of miR-199a-5p in lung fibroblasts. Microarray analysis of
lung fibroblasts transfected with 10 nM of miR-199a-5p mimic or
miR-Neg reveals a significant increase of ACTA2 expression
(*p,0.05), a hallmark of myofibroblast differentiation, as well as a
significant decrease of PPARG expression (**p,0.01), a known
inhibitor of myofibroblast differentiation. Data are expressed as
mean of normalized fluorescence values 6 SEM.
(TIF)
Figure S10 Comparison of transcriptomic changes induced by
miR-199a-5p and a siRNA directed against CAV1. Normal
human pulmonary fibroblasts hFL1 were transfected with pre-
miR-Neg, pre-miR-199a-5p as well as siCAV1 or a control siRNA
(n= 2). RNA samples were harvested at 48 h post-transfection and
expression profiles were determined with pan genomic arrays. (A)
Heatmap comparing the normalized log2 of the ratios between
pre-miR-199a-5p versus pre-miR-Neg or siCAV1 versus siNeg
signals. (B) Venn diagram comparing the set of down-regulated
transcripts following miR-199a-5p and siCAV1. Cut-offs for
selection are equal to 7.0 for the log2 (signal), 0.7 for the log2
(ratio), and 0.05 for the adjusted p-value.
(TIF)
Figure S11 Comparison of gene expression changes between
miR-199a-5p-regulated genes in hFL1 human lungs fibroblasts
and lungs from C57BL/6 mice 14 days after bleomycin injection.
(A) Venn diagram showing the relationships of gene expression
changes between miR-199a-5p transfected lung fibroblasts (two
independent experiments) and lungs from C57BL/6 14 days after
Bleomycin treatment (n = 5 mice). The numbers of genes whose
expression was differentially detected in each condition at p,0.05
are shown. Microarray analysis shows a significant reduction of
CAV2 (B), TGFBRI (C), CCL2 (D), ACTA2 (E) and MMP3 (F)
expression in C57BL/6 mice treated with bleomycin for 14 days
(n = 5) compared with control mice (n = 5). Data are expressed as
mean 6 SEM. ** p,0.01.
(TIF)
Figure S12 Profibrotic genes significantly modulated in lung
fibroblasts by miR-199a-5p independently of CAV1 regulation.
Lung fibroblasts were transfected by miR-199a-5p mimic, si-
CAV1 or negative controls. Microarray analysis shows the
expression of known profibrotic genes: TGFBRI (A), MMP3 (B),
CAV2 (C), PLAU (D) and CCL2 (E) 48 h after transfection. Data are
expressed as mean 6 SEM. *p,0.05, **p,0.01.
(TIF)
Figure S13 Enhanced expression of miR-199a-5p in clinical
samples from patients with liver fibrosis. In situ hybridization assay
was performed to determine the localization of miR-199a-5p in
normal and fibrotic human livers. Results represent one out of
three independent experiments.
(TIF)
Figure S14 Expression of miR-199a-3p in lung fibrosis and
impact of its overexpression on pulmonary fibroblast differentia-
tion. (A) Increased expression of miR-199a-3p and miR-199a-5p
in lung samples from IPF patients (n = 10) compared to control
lung (n= 10). The mean normalized fluorescence intensity for the
agilent probe is displayed; (B) Western blot analysis showing the
effect of miR-199-5p or miR-199a-3p overexpression in hFL1 lung
fibroblasts on SMAD4 and aSMA expression. One representative
experiment out of two is shown.
(TIF)
Figure S15 Transfection of human lung fibroblasts with pre-
miR-199a-5p or pre-miR-21 increases cell motility. Sratch wound
was induced in confluent cell monolayers plated on plastic and
wound closure was measured using image J software (2
independent experiments).
(TIF)
Figure S16 Effect of TGFb on mature and pri-miRNAs forms of
miR-199a in human lung fibroblasts. HFL1 human fibroblasts
were treated or not with 10 nM TGFb for 48 hours. Real Time
TaqMan PCR showing the levels of (A) mature miR-199a-5p and
miR-199a-3p; (B) pri-miR-199a-1 and pri-miR-199a-2. n= 2.
Data are expressed as mean 6 SEM *p,0.05.
(TIF)
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Table S1 List of themes corresponding to ‘‘canonical pathways’’
annotations identified by Ingenuity Pathway Analysis in response to
overexpression of miR-199a-5p or miR-21 in human pulmonary
fibroblasts hFL1. Normal human pulmonary fibroblasts hFL1 were
transfected with pre-miR-Neg, pre-miR-199a-5p or pre-miR-21
(n= 2). RNA samples were harvested at 48 h post-transfection and
expression profiles were determined with whole genome micro-
arrays. The probability to obtain the number of genes in a certain
pathway in the list of differentially expressed genes between either
miR-199a-5p or miR-21 versus miR-Neg was compared with the
representation of the same pathway among all the genes on the
microarray; 2log10 of the Fisher’s exact probability is indicated.
Significant pathways are shown in progressively brighter shades of
orange according to their significance. ns= non significant.
(DOCX)
Table S2 List of themes corresponding to ‘‘canonical pathways’’
annotations identified by Ingenuity Pathway Analysis in lungs
from C57BL/6 mice treated with bleomycin. RNAs extracted
from C57BL/6 mice lungs 14 days after instillation with
bleomycin or PBS were analyzed with whole genome microarrays
(n = 5).The probability to obtain the number of genes in a certain
pathway in the list of differentially expressed genes between
bleomycin and PBS conditions was compared with the represen-
tation of the same pathway among all the genes on the microarray;
2log10 of the Fisher’s exact probability is indicated.
(DOCX)
Table S3 Pulmonary expression of miR-199a-5p in 10 IPF and
10 controls (dataset GEO accession number GSE13316).
(DOCX)
Table S4 List of the 133 genes modulated by miR-199a-5p in
lung fibroblasts that are also dysregulated in lungs from C57BL/6
mice 14 days after bleomycin treatment.
(DOCX)
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